1. SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling
   Yuko Nagamura et al, 2021, Cancers CrossRef
2. Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis
   Simona Corso et al, 2018, Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways CrossRef
3. Fibroblast growth factor receptors as treatment targets in clinical oncology
   Masaru Katoh, 2019, Nature Reviews Clinical Oncology CrossRef
4. Patient-Derived Xenograft: A More Standard “Avatar” Model in Preclinical Studies of Gastric Cancer
   Mingtang Zeng et al, 2022, Frontiers in Oncology CrossRef
5. cMET Exon 14 Skipping: From the Structure to the Clinic
   Nele Van Der Steen et al, 2016, Journal of Thoracic Oncology CrossRef
6. PLEKHA5 regulates the survival and peritoneal dissemination of diffuse-type gastric carcinoma cells with Met gene amplification
   Yuko Nagamura et al, 2021, Oncogenesis CrossRef
7. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer
   Xiuli Wu et al, 2022, Bioorganic Chemistry CrossRef
8. Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns
   Xiangyuan Ma et al, 2017, PLOS ONE CrossRef
9. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
   Fatemeh Moosavi et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
10. Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors
    Hideki Yamaguchi et al, 2022, Cancers CrossRef